The euphoria over Gilead Sciences' (Nasdaq: GILD ) acquisition of Pharmasset (Nasdaq: VRUS ) and Roche's purchase of Anadys Pharmaceuticals seems to have caused memory loss in investors.
But they got a reminder of reality today, when Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
This is nothing new.
Read more.....
0 comments:
Post a Comment